Terms: = Prostate cancer AND BCR, FLJ16453, 613, ENSG00000186716, BCR1, D22S662, D22S11, CML, P11274, PHL, ALL AND Clinical Outcome
27 results:
1. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 prostate cancer Subtypes.
Chappidi MR; Sjöström M; Greenland NY; Cowan JE; Baskin AS; Shee K; Simko JP; Chan E; Stohr BA; Washington SL; Nguyen HG; Quigley DA; Davicioni E; Feng FY; Carroll PR; Cooperberg MR
Eur Urol Oncol; 2024 Apr; 7(2):222-230. PubMed ID: 37474400
[TBL] [Abstract] [Full Text] [Related]
2. Prevalence of tumour-infiltrating CD103
Zhou Q; Ou Y; Dai X; Chen X; Wu S; Chen W; Hu M; Yang C; Zhang L; Jiang H
Br J Cancer; 2023 Apr; 128(8):1466-1477. PubMed ID: 36759726
[TBL] [Abstract] [Full Text] [Related]
3. Identification and validation of a poor clinical outcome subtype of primary prostate cancer with Midkine abundance.
Zhou Q; Yang C; Mou Z; Wu S; Dai X; Chen X; Ou Y; Zhang L; Sha J; Jiang H
Cancer Sci; 2022 Nov; 113(11):3698-3709. PubMed ID: 36018546
[TBL] [Abstract] [Full Text] [Related]
4. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract] [Full Text] [Related]
5. [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients.
Carvalho J; Nunes P; Da Silva ET; Silva R; Lima J; Quaresma V; Figueiredo A
Arch Ital Urol Androl; 2021 Mar; 93(1):21-25. PubMed ID: 33754603
[TBL] [Abstract] [Full Text] [Related]
6.
Cai C; Luo J; Liu Q; Liu Z; Zhao Y; Wu X; Yuegao Y; Lei Y; Lu J; Wang Y; Cai Z; Duan X; Lei M; Gu D; Liu Y
Genet Test Mol Biomarkers; 2021 Feb; 25(2):131-139. PubMed ID: 33596143
[No Abstract] [Full Text] [Related]
7. Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.
Abdelsalam RA; Khalifeh I; Box A; Kalantarian M; Ghosh S; Abou-Ouf H; Lotfi T; Shahait M; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1701-1709. PubMed ID: 32350606
[TBL] [Abstract] [Full Text] [Related]
8. GLUT1 expression in high-risk prostate cancer: correlation with
Meziou S; Ringuette Goulet C; Hovington H; Lefebvre V; Lavallée É; Bergeron M; Brisson H; Champagne A; Neveu B; Lacombe D; Beauregard JM; Buteau FA; Riopel J; Pouliot F
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):441-448. PubMed ID: 31932660
[TBL] [Abstract] [Full Text] [Related]
9. Treatment of Metastatic or High-Risk Solid cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports.
Nicolini A; Ferrari P; Morganti R; Carpi A
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795079
[TBL] [Abstract] [Full Text] [Related]
10. Aberrant KIF20A Expression Is Associated with Adverse clinical outcome and Promotes Tumor Progression in prostate cancer.
Zhang Z; Chai C; Shen T; Li X; Ji J; Li C; Shang Z; Niu Y
Dis Markers; 2019; 2019():4782730. PubMed ID: 31565099
[TBL] [Abstract] [Full Text] [Related]
11. Elevated miR-615-3p Expression Predicts Adverse clinical outcome and Promotes Proliferation and Migration of prostate cancer Cells.
Laursen EB; Fredsøe J; Schmidt L; Strand SH; Kristensen H; Rasmussen AKI; Daugaard TF; Mouritzen P; Høyer S; Kristensen G; Stroomberg HV; Brasso K; Røder MA; Borre M; Sørensen KD
Am J Pathol; 2019 Dec; 189(12):2377-2388. PubMed ID: 31539518
[TBL] [Abstract] [Full Text] [Related]
12. Combined loss of TFF3 and PTEN is associated with lethal outcome and overall survival in men with prostate cancer.
Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
[TBL] [Abstract] [Full Text] [Related]
13. Expression of PD-L1 in tumor-associated nerves correlates with reduced CD8
Mo RJ; Han ZD; Liang YK; Ye JH; Wu SL; Lin SX; Zhang YQ; Song SD; Jiang FN; Zhong WD; Wu CL
Int J Cancer; 2019 Jun; 144(12):3099-3110. PubMed ID: 30537104
[TBL] [Abstract] [Full Text] [Related]
14. Autophagy induced by overexpression of DCTPP1 promotes tumor progression and predicts poor clinical outcome in prostate cancer.
Lu J; Dong W; He H; Han Z; Zhuo Y; Mo R; Liang Y; Zhu J; Li R; Qu H; Zhang L; Wang S; Ma R; Jia Z; Zhong W
Int J Biol Macromol; 2018 Oct; 118(Pt A):599-609. PubMed ID: 29874556
[TBL] [Abstract] [Full Text] [Related]
15.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract] [Full Text] [Related]
16. Genomic Gain of 16p13.3 in prostate cancer Predicts Poor clinical outcome after Surgical Intervention.
Bramhecha YM; Guérard KP; Rouzbeh S; Scarlata E; Brimo F; Chevalier S; Hamel L; Dragomir A; Aprikian AG; Lapointe J
Mol Cancer Res; 2018 Jan; 16(1):115-123. PubMed ID: 28993510
[TBL] [Abstract] [Full Text] [Related]
17. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract] [Full Text] [Related]
18. MR-based prognostic nomogram for prostate cancer after radical prostatectomy.
Zhang YD; Wu CJ; Bao ML; Li H; Wang XN; Liu XS; Shi HB
J Magn Reson Imaging; 2017 Feb; 45(2):586-596. PubMed ID: 27654116
[TBL] [Abstract] [Full Text] [Related]
19. Genetic variants of the CYP1B1 gene as predictors of biochemical recurrence after radical prostatectomy in localized prostate cancer patients.
Gu CY; Qin XJ; Qu YY; Zhu Y; Wan FN; Zhang GM; Sun LJ; Zhu Y; Ye DW
Medicine (Baltimore); 2016 Jul; 95(27):e4066. PubMed ID: 27399092
[TBL] [Abstract] [Full Text] [Related]
20. Impact of Gleason pattern 5 including tertiary pattern 5 on outcomes of salvage treatment for biochemical recurrence in pT2-3N0M0 prostate cancer.
Taguchi S; Shiraishi K; Fukuhara H; Nakagawa K; Morikawa T; Naito A; Kakutani S; Takeshima Y; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Homma Y
Int J Clin Oncol; 2016 Oct; 21(5):975-980. PubMed ID: 27098807
[TBL] [Abstract] [Full Text] [Related]
[Next]
